This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Likely to Venture Into Cannabis Space With Cronos Deal
by Zacks Equity Research
Per sources, Altria (MO) is likely to explore opportunities in the cannabis space through a deal with Cronos.
Legal Pot Shops & Likely IPOs: Is Hemp the Next Big Thing?
by Nitish Marwah
Increasing tolerance and gradual legalization of marijuana has been an increasing trend across America.
Cronos Group (CRON) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed the most recent trading day at $8.20, moving -0.49% from the previous trading session.
Top and Flop ETFs of Last Week
by Sanghamitra Saha
Inside the winning and losing ETFs of the last week.
What Went Wrong With the Marijuana ETF on Wednesday?
by Sanghamitra Saha
Downbeat earnings have weighed on the marijuana ETF lately. Should you buy the dip or wait on the sidelines?
Cannabis Stocks Reporting Earnings & News from HD, AAPL, TSN
by Ryan McQueeney
Ryan McQueeney discusses the latest trade war developments and recaps earnings results from Home Depot and Tyson Foods. He also touches on Apple's supplier concerns. Later, the host chats with Dave Bartosiak about the marijuana stocks reporting earnings this week.
Cronos (CRON) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.
The Earnings Charts of 3 Top Cannabis Stocks
by Tracey Ryniec
The cannabis stocks are hot but will their earnings reports be too?
Do Options Traders Know Something About Cronos (CRON) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cronos (CRON) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Canopy Growth, Cronos and ETFMG Alternative Harvest
Why Marijuana Stocks & ETF Soared Today
by Neena Mishra
Pot stocks soared today as Jeff Sessions' exit and midterm elections have created a more favorable political environment for the industry.
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tilray, Cronos, Canopy Growth, GW Pharmaceuticals and Constellation Brands
Marijuana ETF Enters Bear Territory: What Lies Ahead?
by Sweta Killa
Despite entering into bear territory, the cannabis ETF is up more than 24% over the past three months and the outlook remains bright.
Marijuana Stocks Plummet to Record Low: What's Next?
by Zacks Equity Research
Legalization has long been considered a boon for the marijuana industry.
Canada Legalizes Marijuana: Stocks & ETF in Focus
by Neena Mishra
Canada legalized recreational pot today but it's "sell the news" event for pot stocks that have seen astronomical gains recently.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $11.52, marking a -1.87% move from the previous day.
Cronos Group (CRON) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $9.70 in the latest trading session, marking a -0.82% move from the prior day.
Pot Stocks & ETF: Risks and Rewards
by Neena Mishra
Here is what investors need to know about risks and rewards of investing in the emerging marijuana industry.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Cronos Group (CRON) closed at $10.94, marking a -1.89% move from the previous day.
Wall Street's Reefer Madness, Micron Earnings, & More Stock News
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson discuss the performance of Netflix and other streaming services at the Emmys. The team also chat about the alleged criminal probe facing Elon Musk and Tesla. Later, they discuss marijuana stocks and recap Micron's latest earnings report.
Know How Beverage Stocks Will Gain From Shift to Marijuana
by Rajani Lohia
Cannabis-infused drinks have emerged as an attractive alternative to the problems of the players in the U.S. beverage space, given the health benefits it offers.
Tesla Bull Sells (and Buys Again?) & Dow Rallies Near Highs | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Dow's rally toward all-time highs on the back of strength from financial stocks. He also touches on news related to marijuana producers and reported activist interest in casino giant MGM. Later, the host calls Brian Bolan, a noted Tesla bull, to discuss a major shift in his sentiment for the electric car company.
Marijuana Stocks Soar Again As Wall Street Eyes U.S. Imports
by Ryan McQueeney
Shares of several popular Canadian marijuana producers--including Tilray (TLRY), Canopy Growth (CGC), and Cronos Group (CRON)--were surging once again on Wednesday as Wall Street grows ever-more bullish on the prospects of legalization and U.S. imports.